• Researcher Profile

    Mark Pomerantz, MD

     
    Mark Pomerantz, MD

     
    Physician

    Assistant Professor of Medicine, Harvard Medical School

    Center/Program

    Genitourinary Oncology

    Office phone: 617-632-4524
    Fax: 617-632-2165

    Preferred contact method: appointment phone

    View Physician Profile
     
     

    Research Department

    Medical Oncology

    Interests

    Genetics, Prostate cancer, Testicular cancer

    Area of Research

    Inherited risk of cancer and genetic determinants disease outcome


    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Dana 1230
    Boston, MA 02215

    Biography

    Dr. Mark Pomerantz is a medical oncologist at the Dana-Farber Cancer Institute. Dr. Pomerantz received his undergraduate degree from Yale University and his medical degree from Stanford University. He trained in Internal Medicine at Brigham and Women's Hospital in Boston, Massachusetts. He then pursued a fellowship in Medical Oncology at the Dana-Farber Cancer Institute in Boston. Dr. Pomerantz received his post-doctroal training in cancer genetics with Dr. Matthew Freedman at the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT. He is on faculty at the Dana-Farber Cancer Institute in the Lank Center for Genitourinary Oncology.

    Research

    Inherited risk of cancer and genetic determinants disease outcome

    Dr. Pomerantz's research focuses on the factors associated with cancer risk, with an emphasis on prostate cancer. Prostate cancer develops in the setting of many environmental and inherited risk factors. Since 2006, the inherited component of the disease has come into clearer focus. Multiple genetic markers, inherited from one's parents and highly associated with risk of prostate cancer, have been discovered. However, the mechanism in which these inherited factors predispose one to disease is unknown. Working closely with clinicians, biostatisticians and epidemiologists at Dana-Farber and the Broad Institute, he is actively deciphering this mechanism in an attempt to define the underpinnings of prostate cancer risk. 

View Researcher Directory
View Nurse Directory

Find a Clinical Trial

Support Cancer
Research

Give Now